Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
Abstract Background Immune checkpoint inhibitors (ICIs) has shown remarkable benefit in the treatment of a range of cancer types, although it may initiate immune related adverse events (irAEs) in patients. Some studies have shown that there is a close relationship between the occurrence of irAEs and...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2022-11-01
|
| Schriftenreihe: | BMC Cancer |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s12885-022-10199-x |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|